Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy.
Subscribe to news feed
You are here
Home › For PatientsFor Patients
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance. Our product candidates have the potential to re-define treatment paradigms in a variety of cancers.
We are currently evaluating two drugs for the treatment of prostate, lung, and bladder cancers.
Custirsen (OGX-011)
If you are a patient with advanced prostate cancer, click here to learn about a clinical trial that may be of interest to you.
To learn more about OncoGenex' clinical trials in Prostate Cancer, click here
To learn more about clinical trials of Custirsen (OGX-011) in Lung Cancer, click here.
OGX-427
OGX-427 is a second generation antisense drug which, in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27), a cell survival protein found at elevated levels in many human cancers. The development program for OGX-427 aims to demonstrate inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.
If you are a patient with advanced bladder cancer, click here to learn about a clinical trial that may be of interest to you.
To learn more about OncoGenex' clinical trials in Bladder Cancer, click here.
To learn more about OncoGenex' clinical trials in Prostate Cancer, click here.
To learn more about OncoGenex' clinical trials in Lung Cancer, click here.
To learn more about OncoGenex' clinical trials in Pancreatic Cancer, click here.
